Document:

Amended and Restated Management Supplemental Benefit Plan

 Exhibit (10)(c) 
  

					
		 	 The First American Corporation
 Management Supplemental Benefit Plan
	 	
			
		 	 Amended and Restated
 Effective as of November 1,
2007
	 	

 Contents 
  

  

			
	 Article 1. Introduction
	  	1
	1.1 Background and History	  	1
	1.2 Purpose of the Plan	  	1
	1.3 Gender and Number	  	1
		
	 Article 2. Definitions
	  	2
	2.1 Affiliate	  	2
	2.2 Annuity Starting Date	  	2
	2.3 Basic Plan	  	2
	2.4 Beneficiary	  	3
	2.5 Board of Directors	  	3
	2.6 Change of Control	  	3
	2.7 Code	  	3
	2.8 Committee	  	4
	2.9 Company	  	4
	2.10 Competing Business	  	4
	2.11 Competition	  	4
	2.12 Covered Compensation	  	4
	2.13 Deferred Retirement Date	  	5
	2.14 Disabled	  	5
	2.15 Early Retirement Date	  	5
	2.16 Employee	  	5
	2.17 Employer	  	6
	2.18 ERISA	  	6
	2.19 Executive	  	6
	2.20 Executive Plan	  	6
	2.21 Final Average Compensation	  	6
	2.22 Good Cause	  	6
	2.23 Hours of Service	  	7
	2.24 In Pay Status	  	7
	2.25 Incumbent Directors	  	8
	2.26 Joint and Survivor Annuity	  	8
	2.27 Normal Retirement Date	  	8

  

 i 

			
	2.28 Person	  	9
	2.29 Plan	  	9
	2.30 Pre-Retirement Death Benefit	  	9
	2.31 Retirement Income Benefit	  	9
	2.32 Separation from Service	  	9
	2.33 Specified Employee	  	9
	2.34 Spouse	  	10
	2.35 Surviving Spouse	  	10
	2.36 Years of Credited Service	  	10
		
	 Article 3. Retirement Income Benefits
	  	11
	3.1 Eligibility to Participate	  	11
	3.2 Normal Retirement	  	11
	3.3 Early Retirement	  	12
	3.4 Disabled Executive	  	12
	3.5 Six-Month Delay for Specified Employees	  	12
	3.6 Rehired Executive Not In Pay Status	  	12
		
	 Article 4. Pre-Retirement Death Benefit
	  	13
		
	 Article 5. Vesting of Benefits
	  	14
	5.1 General Rule	  	14
	5.2 Change of Control	  	14
	5.3 Forfeiture in the Event of Competition	  	14
		
	 Article 6. Funding of Benefits
	  	16
		
	 Article 7. Plan Administration
	  	17
	7.1 Committee	  	17
	7.2 Operation of the Committee	  	17
	7.3 Agents	  	18
	7.4 Compensation and Expenses	  	18
	7.5 Committee’s Powers and Duties	  	19
	7.6 Committee’s Decisions Conclusive/Exclusive Benefit	  	19
	7.7 Indemnity	  	20
	7.8 Insurance	  	21
	7.9 Notices	  	22
	7.10 Data	  	22
	7.11 Claims Procedure	  	22
	7.12 Effect of a Mistake	  	25

  

 ii 

			
		
	 Article 8. Amendment and Termination
	  	26
	8.1 Amendment and Termination Generally	  	26
	8.2 Amendment and Termination Following a Change of Control	  	26
		
	 Article 9. Miscellaneous
	  	27
	9.1 No Enlargement of Employee Rights	  	27
	9.2 Benefit Agreement	  	27
	9.3 Exclusion for Suicide or Self-Inflicted Injury	  	27
	9.4 Leave of Absence	  	27
	9.5 Termination for Good Cause	  	27
	9.6 Monthly Payments	  	27
	9.7 Actuarial Equivalence	  	28
	9.8 Withholding	  	28
	9.9 No Examination or Accounting	  	28
	9.10 Records Conclusive	  	28
	9.11 Section 409A	  	28
	9.12 Service of Legal Process	  	28
	9.13 Governing Law	  	28
	9.14 Severability	  	28
	9.15 Missing Persons	  	29
	9.16 Facility of Payment	  	29
	9.17 General Restrictions Against Alienation	  	29
	9.18 Counterparts	  	30
	9.19 Effect of Amendment on Vested Executives	  	30
	9.20 Assignment	  	30

  

 iii 

 Article 1. Introduction 
 1.1 Background and History 
 The First American Corporation Management Supplemental Benefit Plan (“Plan”) was established by the
Board of Directors, effective as of January 1, 1988. Except as otherwise specified, the Plan is now being amended and restated, effective as of November 1, 2007, to amend and clarify certain Plan provisions and to comply with final
regulations under Code section 409A. 
 1.2 Purpose of the Plan 
 The Plan is designed to provide supplemental retirement income and death benefits for certain Executives. 
 1.3 Gender
and Number 
 Except as otherwise indicated by the context, any masculine or feminine terminology shall also include the opposite gender, and the
definition of any term in the singular or plural shall also include the opposite number. 
  

 1 

 Article 2. Definitions 
 The following definitions, set forth in alphabetical order, are used throughout the Plan and have the meaning set forth below. 
 2.1 Affiliate

 “Affiliate” means 
  

	(a)	Any entity or organization that, together with the Company, is part of a controlled group of corporations, within the meaning of Code section 414(b); 

 

	(b)	Any trade or business that, together with the Company, is under common control, within the meaning of Code section 414(c); and 

  

	(c)	Any entity or organization that is required to be aggregated with the Company, pursuant to Code sections 414(m) or 414(o). 

 For purposes of this Plan, however, the term “Affiliate” shall be interpreted such that the phrase “at least 50 percent” will be substituted for
the phrase “at least 80 percent” in each place that it appears in Code section 1563. Additionally, an entity shall be an Affiliate only during the period when the entity has the required relationship, under this Plan
section 2.1, with the Company. 
 2.2 Annuity Starting Date 
 “Annuity Starting Date” means the first day of the first period for which an amount is paid as an annuity. 
 2.3 Basic Plan

 “Basic Plan” means The First American Corporation Pension Plan, a defined benefit pension plan qualified under Code section 401(a), as
amended from time to time. 
  

 2 

 2.4 Beneficiary 
 “Beneficiary” means the person, persons or entity designated in writing by the Executive on forms provided by the Company to receive the Pre-Retirement Death Benefit set forth under Article 4 of the Plan in the event of the
Executive’s death. An Executive may change the designated Beneficiary from time to time by filing a new written designation with the Company, and such designation shall be effective upon receipt by the Company, provided that the Company has
determined that such change in Beneficiary will not result in an “impermissible acceleration” under Code section 409A. If the Company determines that such change in Beneficiary will result in an “impermissible acceleration,”
such intended change will be null and void and the Beneficiary on file prior to such intended change (if any) shall remain the Beneficiary. If an Executive has not designated a Beneficiary, or if a designated Beneficiary is not living or in
existence at the time of the Executive’s death, the Pre-Retirement Death Benefit payable under the Plan shall be paid to the Executive’s Spouse, if then living, and if the Executive’s Spouse is not then living, to the Executive’s
estate. 
 2.5 Board of Directors 
 “Board of
Directors” means the Board of Directors of the Company. 
 2.6 Change of Control 
 “Change of Control” means the occurrence of any of the following: 
  

	(a)	The acquisition by any person, entity or “group” (as defined in section 13(d)(3) of the Securities Exchange Act of 1934, as amended (“Exchange Act”)) as
beneficial owner, directly or indirectly, of securities of the Company representing 25% or more of the combined voting power of the then outstanding securities of the Company. 

  

	(b)	A change in the composition of the Board of Directors occurring within a two-year period, as a result of which fewer than a majority of the directors are Incumbent Directors; or

  

	(c)	Any other event constituting a change in control required to be reported in response to item 6(e) of Schedule 14A of Regulation 14A under the Exchange Act. 

Notwithstanding the foregoing, a Change in Control shall not be deemed to have occurred by reason of the acquisition of Company securities by the Company, any entity
controlled by the Company or any plan sponsored by the Company which is qualified under Code section 401(a) or by reason of the acquisition of Company securities (either directly or indirectly as a result of a merger, consolidation or otherwise) in
a transaction approved by the Incumbent Directors. 
 2.7 Code 
 “Code” means the Internal Revenue Code of 1986, as amended. 
  

 3 

 2.8 Committee 
 “Committee” means the Compensation Committee appointed by the Board of Directors, or any other committee appointed by the Board of Directors to administer this Plan in accordance with Article 7 of the Plan. 
 2.9 Company 
 “Company” means The First American
Corporation. 
 2.10 Competing Business 
 “Competing
Business” means any individual (including the Executive), person, sole proprietorship, joint venture, partnership, corporation, limited liability company, business entity, trust or other entity that competes with, or will compete with, the
Company or an Affiliate in any locality worldwide. A Competing Business includes, without limitation, any start-up or other entity in formation. 
 2.11
Competition 
 “Competition” means any of the following, whether occurring during or after the end of the Executive’s employment with the
Employer: 
  

	(a)	The Executive’s Involvement (as defined in Article 5) in or with a Competing Business; 

  

	(b)	The misappropriation, sale, transfer, use or disclosure of trade secrets, or confidential or proprietary information of the Company or an Affiliate; 

  

	(c)	Any action or attempt by the Executive, directly or indirectly, either for himself or for any other person or entity, to recruit or solicit for hire any employee, officer, director,
consultant, independent contractor or other personnel of the Company or an Affiliate, or to induce or encourage such a person or entity to terminate his, her or its relationship, or breach an agreement, with the Company or an Affiliate; or

  

	(d)	Any action or attempt by the Executive, directly or indirectly, either for himself or for any other person or entity, to solicit or induce any customer or potential customer of the
Company or an Affiliate to cease or not commence doing business, in whole or in part, with or through the Company or an Affiliate, or to do business with any other person, firm, partnership, corporation or any Competing Business.

 2.12 Covered Compensation 
 “Covered
Compensation” means base salary, cash bonus, sales commissions, similar commission-based remuneration and equity-based compensation explicitly designated as Covered Compensation or explicitly designated as compensation for past performance.
“Covered Compensation” excludes any other form of remuneration, including, but not limited to, equity compensation awarded to incentivize future performance, relocation expenses and bonuses, earn-outs and other acquisition-related
consideration, car allowances 

  

 4 

 
and perquisites. Except as otherwise provided by the Committee, “Covered Compensation” also excludes any payments made in connection with a
Separation from Service, including, but not limited to, any bonus paid to an Executive in connection with his Separation from Service during a calendar year in which such Executive has already received a performance bonus. If an Executive dies or
becomes Disabled, his Covered Compensation for that calendar year shall be defined as the Covered Compensation received through the date of death or disability, respectively, and no compensation received thereafter shall be considered Covered
Compensation. Covered Compensation shall for all purposes be deemed paid in the year in which it is actually paid. 
 2.13 Deferred Retirement Date 

 “Deferred Retirement Date” means the date on which an Executive who is actively employed by the Company or an Affiliate incurs a Separation from
Service following attainment of his Normal Retirement Date. 
 2.14 Disabled 
 “Disabled” means an Executive who is, in the determination of the Committee, unable to perform substantially all of the material duties of one’s regular position because of a bodily injury sustained or
disease originating after the date of such person’s designation as an Executive under this Plan. Notwithstanding the foregoing: 
  

	(a)	After an Executive has been Disabled as defined above for a period of 24 continuous months, the Executive will cease to be considered Disabled unless he is unable to perform
any occupation for which he is reasonably fitted by education, training or experience because of such bodily injury or sickness; and 

  

	(b)	An Executive is not Disabled at any time that he is working for pay or profit at any occupation. 

 2.15 Early Retirement Date 
 “Early Retirement Date” means the later of an Executive’s 
  

	 (a)
	 55th birthday; 

  

	(b)	Completion of 15 Years of Credited Service; and 

  

	(c)	Completion of 5 years as an Executive under the Plan and/or the Executive Plan (which requirement may be waived unilaterally only by the Board of Directors or the Committee).

 2.16 Employee 
 “Employee”
means any person who is employed by the Company or Affiliate and who is classified as a common-law Employee in the employment records of the Company or an Affiliate (other than a leased employee within the meaning of Code section 414(n)(2)).

  

 5 

 2.17 Employer 
 “Employer” means the Company and any Affiliate. 
 2.18 ERISA 
 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 
 2.19 Executive 

“Executive” means a key management or key highly compensated employee of the Employer who has been specifically designated by the Board of Directors or the
Committee, or the designee of either, as eligible to participate in this Plan, as evidenced by execution by the Executive of the benefit agreement contemplated by Plan section 9.2. 
 2.20 Executive Plan 
 “Executive Plan” means The First American Corporation Executive Supplemental Benefit
Plan. 
 2.21 Final Average Compensation 
 “Final
Average Compensation” means the Executive’s average one-year Covered Compensation for the five-year period ending on December 31 of the calendar year immediately preceding the calendar year in which the Executive has a Separation from
Service. 
 2.22 Good Cause 
 “Good Cause”
means, with respect to an Employee’s Separation from Service with his Employer, a termination for: 
  

	(a)	Employee’s breach of any fiduciary duty to Employer; 

  

	(b)	Employee’s failure or refusal to comply with laws or regulations applicable to Employer and its business or the policies of Employer governing the conduct of its employees;

  

	(c)	Employee’s gross incompetence in the performance of Employee’s job duties; 

  

	(d)	Commission by Employee of any criminal or fraudulent acts against Employer; 

  

	(e)	The failure of Employee to perform duties consistent with a commercially reasonable standard of care; 

  

	(f)	Employee’s failure or refusal to perform Employee’s job duties; or 

  

	(g)	Any gross or willful conduct of Employee resulting in loss to Employer or any other Affiliate of the Company, or damage to the reputation of Employer or any other Affiliate of the
Company. 

  

 6 

 2.23 Hours of Service 
 “Hours of Service” means: 
  

	(a)	Each hour for which an Executive is paid or entitled to payment by the Company or an Affiliate for the performance of duties. 

  

	(b)	Each hour for which an Executive is paid or entitled to payment by the Company or an Affiliate on account of a period of time during which no duties are performed (irrespective of
whether the employment relationship has terminated) due to vacation, holiday, illness, incapacity (including disability) layoff, jury duty, or leave of absence. 

  

	(c)	Each hour for which back pay (irrespective of mitigation of damages) for an Executive is either awarded or agreed to by the Company or an Affiliate, with no duplication of credit
for hours under subsections (a) or (b) and this subsection. 

  

	(d)	Each hour credited pursuant to applicable ERISA regulations for unpaid periods of absence for service in the United States armed forces or Public Health Service during which an
Executive’s reemployment rights are guaranteed by law, provided that the Executive is reemployed by the Company or an Affiliate within the time limits prescribed by such law. 

 Notwithstanding the foregoing, no more than 501 Hours of Service shall be credited to an Executive on account of any single continuous period during which the
Executive performs no duties. 
 To the extent a record of an Executive’s hours of employment is not maintained by the Company or an Affiliate, the
Executive shall be credited with 10 Hours of Service for each day for which the Executive would be required to be credited with at least one Hour of Service. 
 All Hours of Service shall be determined and credited to computation periods in accordance with reasonable standards and policies consistent with United States Department of Labor Regulations
sections 2530.200b-2(b) and (c). 
 2.24 In Pay Status 
 “In Pay Status” means, with respect to a benefit, that an Executive or Beneficiary has met all of the requirements to receive such benefit, and it is being paid or is about to be paid to such Executive or Beneficiary. No benefit
can be paid under this Plan unless the Executive has incurred a Separation from Service. 
  

 7 

 2.25 Incumbent Directors 
 “Incumbent Directors” means directors who either are: 
  

	(a)	Directors of the Company as of November 1, 2007; or 

  

	(b)	Elected, or nominated for election, to the Board of Directors with the affirmative votes of at least two-thirds of the Incumbent Directors at the time of such election or nomination
(but shall not include an individual not otherwise an Incumbent Director whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company. 

 2.26 Joint and Survivor Annuity 
 “Joint and Survivor
Annuity” means an annuity that provides equal monthly payments for the life of the Executive and, after his death, a reduced annuity (“survivor annuity”) for the life of the Executive’s Surviving Spouse, if any. The monthly
payment under the survivor annuity to a Surviving Spouse shall be equal to 50% of the amount of the monthly payment made to the Executive during their joint lives if the Surviving Spouse is not more than five years younger, or is older, than the
Executive at the time benefits begin. If the Surviving Spouse is more than five years younger than the Executive, the survivor annuity will be determined with reference to the actual age of the Surviving Spouse at the time benefits begin and will be
reduced to produce the actuarial equivalent of a 50% survivor annuity for a Surviving Spouse who is five years younger than the Executive. 
 If the
Executive is not married at the time that Plan benefits commence, the Joint and Survivor Annuity means an annuity providing equal monthly payments for the lifetime of the Executive with no survivor benefits. 
 2.27 Normal Retirement Date 
 “Normal Retirement Date” means
the last day of the month coinciding with or next following the later of an Executive’s: 
  

	 (a)
	 62nd birthday; 

  

	(b)	Completion of 10 Years of Credited Service (which requirement may be waived unilaterally only by the Board of Directors or the Committee); or 

  

	(c)	Completion of 5 years as an Executive under the Plan and/or the Executive Plan (which requirement may be waived unilaterally only by the Board of Directors or the Committee).

  

 8 

 2.28 Person 
 “Person” means any individual, partnership, joint venture, association, joint company, corporation, trust, limited liability company, unincorporated organization, a group, a government or other department, agency or political
subdivision thereof or any other person or entity as contemplated by the Exchange Act. 
 2.29 Plan 
 “Plan” means The First American Corporation Management Supplemental Benefit Plan. The Plan was originally named The First American Financial Corporation
Management Supplemental Benefit Plan and took its current name effective as of May 12, 2000, to reflect the change in the name of the Company. 
 2.30 Pre-Retirement Death Benefit 
 “Pre-Retirement Death Benefit” means the benefit payable, as set forth in Article 4, to the
Beneficiary of an Executive who dies prior to the commencement of his Retirement Income Benefit. 
 2.31 Retirement Income Benefit 
 “Retirement Income Benefit” means 1/12 of the benefit described in Article 3 payable as a monthly annuity. 
 2.32 Separation from Service 
 “Separation from Service”
means that an Executive who ceases to be an Employee or otherwise separates from the service of the Company or an Affiliate on account of the Executive’s retirement, death or other termination of employment. Whether or not an Executive has
incurred a Separation from Service will be based on all surrounding relevant circumstances, including, but not limited to, the reasonable belief of both the Executive and the Company (or Affiliate) that the Executive will perform no future services
for the Company or an Affiliate as an Employee. For purposes of this defined term, no Separation from Service will be deemed to have occurred if the Executive transfers employment from the Company or an Affiliate to another member of the
Company’s Code section 414 controlled group. For this purpose, controlled group membership will include the Company and all Affiliates. 
 2.33
Specified Employee 
 “Specified Employee” means an Executive qualifying as a “key employee” for purposes of Code section 416
(determined without regard to Code section 416(i)(5)) by satisfying any one of the following conditions at any time during the 12-month period ending on each December 31 (“Identification Date”): 
  

	(a)	The Executive is among the top-paid 50 officers of the Company with annual compensation (within the meaning of Code section 415(c)(3)) in excess of $145,000 (subject to
cost-of-living adjustments); 

  

 9 

	(b)	The Executive is a five-percent owner; or 

  

	(c)	The Executive is a one-percent owner and has annual compensation in excess of $150,000. 

 If an individual is a key employee as of an Identification Date, including an individual who acknowledges his Specified Employee status to the Company immediately prior to the date his Retirement Income Benefit
commences, the individual shall be treated as a Specified Employee for the 12-month period beginning on April 1 following the Identification Date. For the limited purpose of applying the “one-percent” and “five-percent”
ownership rules, ownership is determined with respect to the entity for which the Employee provides services. The Code’s controlled and affiliated service group rules do not apply when determining an Executive’s ownership interests.
Notwithstanding the foregoing, an individual shall not be treated as a Specified Employee unless any stock of the Company or any Affiliate is publicly traded on an established securities market or otherwise. 
 Notwithstanding the above, the Company may (but is not required to) adopt an alternative method for identifying Specified Employees, provided such method satisfies the
requirements set forth at Treasury Regulations section 1.409A-1(i)(5). 
 2.34 Spouse 
 “Spouse” means with respect to an Executive, a person of the opposite sex from the Executive, who is the Executive’s husband or wife (as applicable) under
applicable state law to whom the Executive has been legally married during the 12-month period immediately preceding the Executive’s date of death, if such death is earlier than the Executive’s Early, Normal or Deferred Retirement Date, or
the person to whom the Executive is married as of his Annuity Starting Date. No individual, including an individual of the opposite sex, shall be the Spouse of an Executive on account of the fact that the individual is registered as the domestic
partner of the Executive under state law, even if state law provides that the domestic partners shall have the same rights, protections, and benefits, under state law, as married persons. No individual shall be the Spouse of an Executive unless the
person would be treated as the “Spouse” of the Executive under 1 USC section 7 (relating to the definition of a “Spouse” for purposes of federal law, as added by the Defense of Marriage Act). 
 2.35 Surviving Spouse 
 “Surviving Spouse” means the Spouse
of a deceased Executive who was the Spouse to whom the Executive was married at the time that Plan benefits commenced and who is living at the time of the Executive’s death after benefit commencement. 
 2.36 Years of Credited Service 
 “Year of Credited Service”
means years of benefit service as defined in Article 3 of the Basic Plan. In making this determination, and notwithstanding the prior sentence, the provisions of Plan section 9.4 relating to leaves of absence shall control over any contrary
provisions in the Basic Plan. 
  

 10 

 Article 3. Retirement Income Benefits 
 3.1 Eligibility to Participate 
 Subject to Plan section 5.2, each Executive who either: 
  

	(a)	Reaches his Normal Retirement Date while an Executive employed by an Employer and retires on or after such date; or 

  

	(b)	Retires on or after his Early Retirement Date but prior to reaching Normal Retirement Date, 

 shall be eligible to receive a Retirement Income Benefit under this Plan upon the Executive’s Separation from Service. 
 3.2 Normal Retirement 
 Subject to Plan section 3.5 and to the Executive’s execution of a separation agreement and annual written
certification that he is not in Competition with the Company or any Affiliate, each in the form prescribed by the Committee or its designee, an Executive who incurs a Separation from Service (subject to Article 4 if such Separation from Service is
as a result of a death) on or after his Normal Retirement Date shall be entitled to a Retirement Income Benefit equal to 15% of his Final Average Compensation and payable in the form of a Joint and Survivor Annuity commencing on the last day of the
month following the month in which the Executive’s Separation from Service occurs. 
 Notwithstanding the foregoing, an Executive’s Retirement
Income Benefit shall be reduced by the amount of any payments that are required to be made to a Spouse, former Spouse, child, or other dependant pursuant to: 
  

	(a)	A valid state domestic relations order that is a judgment, decree, or order under state community property or domestic relations law and that relates to the provision of child
support, alimony, or marital property rights of an Executive’s Spouse, child or other dependent; or 

  

	(b)	In the event of a divorce and after the divorce decree has been issued, a property settlement signed by the Executive, the Executive’s former Spouse, and any other individual
named within the agreement to receive Plan funds. 

  

 11 

 3.3 Early Retirement 
 Subject to Plan section 3.5 and to the Executive’s execution of a separation agreement and annual written certification that he is not in Competition with the Company, or any Affiliate, each in the form prescribed by the Committee or
its designee, an Executive who incurs a Separation from Service prior to his Normal Retirement Date, but after reaching his Early Retirement Date, shall be entitled to a Retirement Income Benefit payable in the form of a Joint and Survivor Annuity
commencing on the last day of the month following the month in which the Executive’s Separation from Service occurs equal to: 
  

	(a)	The Retirement Income Benefit that the Executive would have received under Plan section 3.2 above had his date of Separation from Service been on or after the Executive’s
Normal Retirement Date; 

  

	(b)	Reduced by the product of 7.143% and the number of years (rounded up) by which the Executive’s Separation from Service precedes his Normal Retirement Date.

 3.4 Disabled Executive 
 A Disabled
Executive shall be deemed to be an Executive during the period of his Disability and shall continue to be eligible for early retirement benefits under Plan section 3.3, normal retirement benefits under Plan section 3.2 and a Pre-Retirement
Death Benefit under Article 4, and shall be credited with Years of Credited Service for such period regardless of the nonperformance of services for the Company or an Affiliate. A Disabled Executive’s benefit payments, if any, under this Plan
will commence to a vested Executive only upon his Separation from Service. 
 3.5 Six-Month Delay for Specified Employees 
 If an Executive is determined by the Committee to be a Specified Employee, payment of the Executive’s Retirement Income Benefit will not commence prior to the last
day of the month following the six-month anniversary of the Executive’s Separation from Service. Additionally, an Executive must notify the Company to affirm whether or not he is a Specified Employee by virtue of the one-percent and
five-percent ownership thresholds set forth at Treasury Regulations section 1.409A-1(i) and the Company will not be responsible for any consequences to the Executive as a result of Executive’s failure to so notify the Company. If an
Executive’s normal, early or deferred Retirement Income Benefit is subject to this six-month delay, the Executive will be entitled to receive a one-time lump sum payment equal to the annuity payments delayed by the above six-month delay.

 3.6 Rehired Executive Not In Pay Status 
 An Executive
who has a Separation from Service before he is In Pay Status and subsequently is re-employed by the Company or an Affiliate shall not resume his status as an Executive unless approved by the Committee. 
  

 12 

 Article 4. Pre-Retirement Death Benefit 
 The Beneficiary of an Executive who dies: 
  

	(a)	while an Executive, or 

  

	(b)	after Separation from Service with a vested Retirement Income Benefit, but prior to commencement of payment of his Retirement Income Benefit, 

 shall be entitled to receive a Pre-Retirement Death Benefit consisting of 10 annual amounts, each equal to 50% of the Executive’s Final Average Compensation,
commencing as soon as practicable after the Executive’s death. Commencement of the Beneficiary’s Pre-Retirement Death Benefit will begin in the same calendar year as the Executive’s death, or, to the extent distribution in the same
calendar year is not administratively practicable, then in no event more than 90 days into the next successive calendar year. 
  

 13 

 Article 5. Vesting of Benefits 
 5.1 General Rule 
 An Executive will be 100% vested in his Retirement Income Benefit if he is an Executive on or after
attaining his Early Retirement Date or Normal Retirement Date and will be 100% vested in his Pre-Retirement Death Benefit if he dies while an Executive. 
 5.2 Change of Control 
  

	(a)	All Executives shall be 100% vested in all of their Plan benefits upon a Change of Control. Such benefits shall be determined in accordance with the provisions of the Plan as in
effect on the date of the Change of Control, regardless of subsequent amendments to or a complete termination of the Plan. 

  

	(b)	Notwithstanding any other provision of the Plan and subject to Plan section 3.5, an Executive who incurs a Separation from Service after a Change of Control shall be entitled
to a Retirement Income Benefit in the form of a Joint and Survivor Annuity commencing on the last day of the month following such Separation from Service equal to the Retirement Income Benefit that the Executive would have been entitled to receive
under Plan section 3.2 as if he had attained his Normal Retirement Date on the date of the Executive’s Separation from Service. 

 5.3 Forfeiture in the Event of Competition 
  

	(a)	In the event an Executive who has not attained his Early Retirement Date prior to September 1, 2005, engages in Competition (as defined below) with the Company or an Affiliate
on or after September 1, 2005, such Executive and his Beneficiary shall forfeit all right, title and interest in and to any benefits payable under the Plan. 

  

	(b)	In the event an Executive who has attained his Early Retirement Date but has not attained his Normal Retirement Date prior to September 1, 2005, engages in Competition with the
Company or an Affiliate on or after September 1, 2005, such Executive and his Beneficiary shall not be entitled to receive the Retirement Income Benefit described in Plan section 3.2 or the Pre-Retirement Death Benefit described in Article
4 and shall not accrue any additional benefits pursuant to the terms of the Plan on or after September 1, 2005, and shall only be entitled to those benefits that the Executive would have been entitled to had he incurred a Separation from
Service on September 1, 2005. 

  

 14 

	(c)	“Involvement” means the Executive’s relationship with, or provision of services to or for, a Competing Business in any manner whatsoever, directly or indirectly,
including, without limitation, as a shareholder, member, partner, director, officer, manager, investor, organizer, founder, employee, consultant, advisor, independent contractor, owner, trustee, beneficiary, co-venturer, lender, distributor or
agent, or in any other capacity. The ownership of less than a 2% equity or debt interest in a corporation whose equity securities are publicly traded in a recognized stock exchange or traded in the over-the-counter market shall not be deemed
Involvement with a Competing Business under this Plan, even though the corporation may be a competitor of the Company or an Affiliate. 

  

	(d)	Nothing in this Plan section 5.3 restrains an Executive in any way from engaging in any lawful profession, trade or business of any kind. Rather, this Plan section 5.3
provides for a forfeiture of certain benefits in the event of Competition with the Company or an Affiliate. 

  

 15 

 Article 6. Funding of Benefits 
 The Plan shall be unfunded. All benefits payable under the Plan shall be paid from the Company’s general assets, and nothing contained in the Plan shall require the Company to set aside or hold in trust any funds
for the benefit of an Executive or his Beneficiary, who shall have the status of a general unsecured creditor with respect to the Company’s obligation to make payments under the Plan. Any funds of the Company available to pay benefits under the
Plan shall be subject to the claims of general creditors of the Company and may be used for any purpose by the Company. 
  

 16 

 Article 7. Plan Administration 
 7.1 Committee 
  

	(a)	Except as otherwise provided in the Plan, the Committee shall be the administrator of the Plan, within the meaning of ERISA section 3(16)(A). The Committee shall generally
administer the Plan. 

  

	(b)	The Committee may be composed of as many members as the Board of Directors may appoint in writing from time to time. The Board of Directors may also delegate to another person the
power to appoint and remove members of the Committee. 

  

	(c)	The Company by action of an officer or the Chairperson of the Committee, or if there is no Chairperson, then by unanimous consent of the members of the Committee, may appoint
Committee members from time to time. Members of the Committee may, but need not, be Employees. 

  

	(d)	A member of the Committee may resign by delivering his written resignation to the Committee. The resignation shall be effective as of the date it is received by the Committee or
such other later date as is specified in the resignation notice. A Committee member may be removed at any time and for any reason by the Company by action of any of its officers, the Chairman of the Committee, or by unanimous consent of the
remaining members of the Committee. Any Employee appointed to the Committee shall automatically cease to be a member of the Committee, effective on the date that he ceases to be an Employee, unless the Chairman of the Committee, an officer of the
Company, or all of the Committee members unanimously specify otherwise in writing. 

 7.2 Operation of the Committee 
  

	(a)	A majority of the members of the Committee at the time in office shall constitute a quorum for the transaction of business. All resolutions adopted and other actions taken by the
Committee at any meeting shall be by the vote of a majority of those present at any such meeting. Upon the concurrence of all of the members in office at the time, action by the Committee may be taken otherwise than at a meeting.

  

	(b)	The members of the Committee may elect one of their members as Chair and may elect a Secretary who may, but need not, be a member of the Committee. 

  

	(c)	The members of the Committee may authorize one or more of their members or any agent to execute or deliver any instrument or instruments on their behalf. The members of the
Committee may allocate any of the Committee’s powers and duties among individual members of the Committee. 

  

 17 

	(d)	The Committee may appoint one or more subcommittees and delegate any of its discretionary authority and such of its powers and duties, as it deems desirable to any such
subcommittee. The members of any such subcommittee shall consist of such persons as the Committee may appoint. 

  

	(e)	All resolutions, proceedings, acts, and determinations of the Committee, with respect to the administration of the Plan, shall be recorded; and all such records, together with such
documents and instruments as may be necessary for the administration of the Plan, shall be preserved by the Committee. 

  

	(f)	Subject to the limitations contained in the Plan, the Committee shall be empowered from time to time in its discretion to establish rules for the exercise of the duties imposed upon
the Committee under the Plan. 

 7.3 Agents 
  

	(a)	The Board of Directors, the Company, or the Committee may delegate such of its powers and duties as it deems desirable to any person, in which case every reference herein made to
the Board of Directors, Company, or the Committee (as applicable) shall be deemed to mean or include the delegated persons as to matters within their jurisdiction. 

  

	(b)	The Board of Directors, the Company, or the Committee may also appoint one or more persons or agents to aid it in carrying out its duties and delegate such of its powers and duties
as it deems desirable to such persons or agents. 

  

	(c)	The Board of Directors, the Company, or the Committee may employ such counsel, auditors, and other specialists and such clerical and other services as it may require in carrying out
the provisions of the Plan, with the expenses therefore paid, as provided in Plan section 7.4. 

 7.4 Compensation and Expenses 

  

	(a)	A member of the Committee shall serve without compensation for services as a member. Any member of the Committee may receive reimbursement of expenses properly and actually incurred
in connection with his services as a member of the Committee, as provided in this Article 7. 

  

	(b)	All expenses of administering the Plan shall be paid by the Company. 

  

 18 

 7.5 Committee’s Powers and Duties 
 Except as otherwise provided in this Plan, the Company shall have responsibility for any settlor duties, powers or functions (e.g., the right to amend and terminate the Plan) and except as otherwise provided in
the Plan, the Committee shall have responsibility for the general administration of the Plan and for carrying out its provisions. The Committee shall have such powers and duties as may be necessary to discharge its functions hereunder, including the
following: 
  

	(a)	To establish rules, policies, and procedures for administration of the Plan; 

  

	(b)	To construe and interpret the Plan, to decide all questions of eligibility, and to determine the amount, manner, and time of payment of any benefits hereunder;

  

	(c)	To make a determination as to the right of any person to a benefit and the amount thereof; 

  

	(d)	To obtain from the Company such information as shall be necessary for the proper administration of the Plan; 

  

	(e)	To prepare and distribute information explaining the Plan; 

  

	(f)	To keep all records necessary for the operation and administration of the Plan; 

  

	(g)	To prepare and file any reports, descriptions, or forms required by the Code or ERISA; and 

  

	(h)	To designate or employ agents and counsel (who may also be persons employed by the Company) and direct them to exercise the powers of the Committee. 

 7.6 Committee’s Decisions Conclusive/Exclusive Benefit 
 The
Committee shall have the exclusive right and discretionary authority to interpret the terms and provisions of the Plan and to resolve all questions arising thereunder, including the right to resolve and remedy ambiguities, inconsistencies, or
omissions in the Plan, provided, however, that the construction necessary for the Plan to conform to the Code and ERISA shall in all cases control. Benefits under this Plan will be paid only if the Committee decides in its discretion that the
Executive, Surviving Spouse or Beneficiary is entitled to them. The Committee shall endeavor to act in such a way as not to discriminate in favor of any class of Executives or other persons. Any and all disputes with respect to the Plan that may
arise involving Executives will be referred to the Committee, and its decisions shall be final, conclusive, and binding. All findings of fact, interpretations, determinations, and decisions of the Committee in respect of any matter or question
arising under the Plan shall be final, conclusive, and binding upon all persons, including, without limitation, Executives, and any and all other persons having, or claiming to have, any interest in or under the Plan and shall be given the maximum
possible deference allowed by law. 
  

 19 

 The Committee shall administer the Plan for the exclusive benefit of Executives and their Beneficiaries. 
 7.7 Indemnity 
  

	(a)	The Company (including any successor employer, as applicable) shall indemnify and hold harmless each of the following persons (“Indemnified Persons”) under the terms and
conditions of subsection (b). 

  

	 	(1)	The Committee; and 

  

	 	(2)	Each Employee, former Employee, current and former members of the Committee, or current or former members of the Board of Directors who have, or had, responsibility (whether by
delegation from another person, an allocation of responsibilities under the terms of this Plan document, or otherwise) for a fiduciary duty, a non-fiduciary settlor function (such as deciding whether to approve a plan amendment), or a non-fiduciary
administrative task relating to the Plan. 

  

	(b)	The Company shall indemnify and hold harmless each Indemnified Person against any and all claims, losses, damages, and expenses, including reasonable attorneys’ fees and court
costs, incurred by that person on account of his good faith actions or failures to act with respect to his responsibilities relating to the Plan. The Company’s indemnification shall include payment of any amounts due under a settlement of any
lawsuit or investigation, but only if the Company agrees to the settlement. 

  

	 	(1)	An Indemnified Person shall be indemnified under this Plan section 7.7 only if he notifies an Appropriate Person (defined below) at the Company of any claim asserted against or
any investigation of the Indemnified Person that relates to the Indemnified Person’s responsibilities with respect to the Plan. 

  

	 	(A)	An “Appropriate Person” is one or more of the following individuals at the Company: 

  

	 	(i)	The Chief Executive Officer, 

  

	 	(ii)	The Chief Financial Officer, or 

  

	 	(iii)	Its General Counsel. 

  

	 	(B)	The notice may be provided orally or in writing. The notice must be provided to the Appropriate Person promptly after the Indemnified Person becomes aware of the claim or
investigation. No indemnification shall be provided under this Plan section 7.7 to the extent that the Company is materially prejudiced by the unreasonable delay of the Indemnified Person in notifying an Appropriate Person of the claim or
investigation. 

  

 20 

	 	(2)	An Indemnified Person shall be indemnified under this Plan section 7.7 with respect to attorneys’ fees, court costs, or other litigation expenses or any settlement of such
litigation only if the Indemnified Person agrees to permit the Company to select counsel and to conduct the defense of the lawsuit and agrees not to take any action in the lawsuit that the Company believes would be prejudicial to the Company’s
interests. 

  

	 	(3)	No Indemnified Person, including an Indemnified Person who is a former Employee, shall be indemnified under this Plan section 7.7 unless he makes himself reasonably available
to assist the Company with respect to the matters in issue and agrees to provide whatever documents, testimony, information, materials, or other forms of assistance that the Company shall reasonably request. 

  

	 	(4)	No Indemnified Person shall be indemnified under this Plan section 7.7 with respect to any action or failure to act that is judicially determined to constitute or be
attributable to the gross negligence or willful misconduct of the Indemnified Person. 

  

	 	(5)	Payments of any indemnity under this Plan section 7.7 shall only be made from assets of the Company. The provisions of this Plan section 7.7 shall not preclude or limit
such further indemnities or reimbursement under this Plan as allowable under applicable law, as may be available under insurance purchased by the Company, or as may be provided by the Company under any by-law, agreement or otherwise, provided that
no expense shall be indemnified under this Plan section 7.7 that is otherwise indemnified by the Company, by an insurance contract purchased by the Company, or by this Plan. 

 7.8 Insurance 
 The Committee may authorize the purchase of insurance
to cover any liabilities or losses occurring by reason of the act or omission of any Committee member or its designee. To the extent permitted by law, the Committee may purchase insurance covering any member (or its designee) for any personal
liability of such Committee member (or its designee) with respect to any administrative responsibilities under this Plan. Any Committee member (or its designee) may also purchase insurance for his own account covering any personal liability under
this Plan. 
  

 21 

 7.9 Notices 
 Each
Executive shall be responsible for furnishing to the Company his current address. The Executive shall also be responsible for notifying the Company of any change in the above information. If an Executive does not provide the above information to the
Company, the Committee may rely on the address of record of the Executive on file with the Company’s personnel office. 
 All notices or other
communications from the Committee to an Executive (who is a current Employee) shall be deemed given and binding upon that person for all purposes of the Plan when delivered by e-mail to the Executive’s individually designated e-mail address at
the Company and all notices or other communications from the Committee to an Executive (who is a former Employee) shall be deemed given and binding upon that person for all purposes of the Plan when delivered to, or when mailed first-class mail,
postage prepaid, and addressed to that person at his address last appearing on the Committee’s records, and the Committee, and the Company shall not be obliged to search for or ascertain his whereabouts. 
 All notices or other communications from the Executive required or permitted under this Plan shall be provided to the person specified by the Committee, using such
procedures as are prescribed by the Committee. The Committee may require that the oral notice or communication be provided by telephoning a specific telephone number and, after calling that telephone number, by following a specified procedure. Any
oral notice or oral communication from an Executive that is made in accordance with procedures prescribed by the Committee shall be deemed to have been duly given when all information requested by the person specified by the Committee is provided to
such person, in accordance with the specified procedures. 
 7.10 Data 
 All persons entitled to benefits from the Plan must furnish to the Committee such documents, evidence, or information, as the Committee considers necessary or desirable for the purpose of administering the Plan, and
it shall be a condition of the Plan that each such person must furnish such information and sign such documents as the Committee may require before any benefits become payable from the Plan. 
 7.11 Claims Procedure 
 All decisions made under the procedure set out
in this Plan section 7.11 shall be final, and there shall be no further right of appeal. No lawsuit may be initiated by any person before fully pursuing the procedures set out in this Plan section 7.11, including the appeal permitted
pursuant to subsection (c) below. 
  

	(a)	The right of an Executive or any other person entitled to claim a benefit under the Plan (collectively “Claimants”) to a benefit shall be determined by the Committee,
provided, however, that the Committee may delegate its responsibility to any person. 

  

 22 

	 	(1)	The Claimant (or an authorized representative of a Claimant) may file a claim for benefits by written notice to the Committee. The Committee shall establish procedures for
determining whether a person is authorized to represent a Claimant. 

  

	 	(2)	Any claim for benefits under the Plan, pursuant to this Plan section 7.11, shall be filed with the Committee no later than three months after the date of the Executive’s
Separation from Service. The Committee in its sole discretion shall determine whether this limitation period has been exceeded. 

  

	 	(3)	Notwithstanding anything to the contrary in this Plan, the following shall not be a claim for purposes of this Plan section 7.11: 

  

	 	(A)	A request for determination of eligibility, participation, or benefit calculation under the Plan without an accompanying claim for benefits under the Plan. The determination of
eligibility, participation, or benefit calculation under the Plan may be necessary to resolve a claim, in which case such determination shall be made in accordance with the claims procedures set forth in this Plan section 7.11.

  

	 	(B)	Any casual inquiry relating to the Plan, including an inquiry about benefits or the circumstances under which benefits might be paid under the Plan. 

  

	 	(C)	A claim that is defective or otherwise fails to follow the procedures of the Plan (e.g., a claim that is addressed to a party other than the Committee or an oral claim).

  

	 	(D)	An application or request for benefits under the Plan. 

  

	(b)	If a claim for benefits is wholly or partially denied, the Committee shall, within a reasonable period of time, but no later than 90 days after receipt of the claim, notify the
Claimant of the denial of benefits. If special circumstances justify extending the period up to an additional 90 days, the Claimant shall be given written notice of this extension within the initial 90-day period, and such notice shall set
forth the special circumstances and the date a decision is expected. A notice of denial 

  

	 	(1)	Shall be written in a manner calculated to be understood by the Claimant; and 

  

	 	(2)	Shall contain 

  

	 	(A)	The specific reasons for denial of the claim; 

  

	 	(B)	Specific reference to the Plan provisions on which the denial is based; 

  

 23 

	 	(C)	A description of any additional material or information necessary for the Claimant to perfect the claim, along with an explanation as to why such material or information is
necessary; and 

  

	 	(D)	An explanation of the Plan’s claim review procedures and the time limits applicable to such procedures, including a statement of the Claimant’s right to bring a civil
action under ERISA section 502(a) following an adverse determination on review. 

  

	(c)	Within 60 days of the receipt by the Claimant of the written denial of his claim or, if the claim has not been granted, within a reasonable period of time (which shall not be less
than the 90 or 180 days described in subsection (b) above), the Claimant (or an authorized representative of a Claimant) may file a written request with the Committee that it conduct a full review of the denial of the claim. In connection with
the Claimant’s appeal, upon request, the Claimant may review and obtain copies of all documents, records and other information relevant to the Claimant’s claim for benefits (but not including any document, record or information that is
subject to any attorney–client or work–product privilege) and may submit issues and comments in writing. The Claimant may submit written comments, documents, records, and other information relating to the claim for benefits. All comments,
documents, records, and other information submitted by the Claimant shall be taken into account in the appeal without regard to whether such information was submitted or considered in the initial benefit determination. 

  

	(d)	The Committee shall deliver to the Claimant a written decision on the claim promptly, but no later than 60 days after the receipt of the Claimant’s request for such review,
unless special circumstances exist that justify extending this period up to an additional 60 days. If the period is extended, the Claimant shall be given written notice of this extension during the initial 60-day period and such notice shall
set forth the special circumstances and the date a decision is expected. The decision on review of the denial of the claim 

  

	 	(1)	Shall be written in a manner calculated to be understood by the Claimant; 

  

	 	(2)	Shall include specific reasons for the decision; 

  

	 	(3)	Shall contain specific references to the Plan provisions on which the decision is based; 

  

	 	(4)	Shall contain a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to, and other information relevant to the Claimant’s
claim for benefits. Whether a document, record, or other information is relevant to a claim for benefits shall be determined by reference to U.S. Department of Labor Regulations section 2560; and 

  

 24 

	 	(5)	Shall contain a statement of the Claimant’s right to bring a civil action under ERISA section 502(a) following an adverse determination on review.

  

	(e)	No lawsuit may be initiated by any person before fully pursuing the procedures set out in this Plan section 7.11, including the appeal permitted pursuant to subsection (c)
above. In addition, no legal action may be commenced later than 365 days subsequent to the date of the written response of the Committee to a Claimant’s request for review pursuant to subsection (d) above. 

 7.12 Effect of a Mistake 
 In the event of a mistake or misstatement
as to the eligibility, participation, or service of any Executive or the amount of payments made or to be made to an Executive, the Committee shall, if possible, cause to be withheld or accelerated or otherwise make adjustment of the amounts of
payments as will, in its sole judgment, result in the Executive receiving the proper amount of payments under the Plan. 
  

 25 

 Article 8. Amendment and Termination 
 8.1 Amendment and Termination Generally 
 The Plan may be amended or terminated by the Company, acting through its
Board of Directors (or the Compensation Committee or other designee of the Board of Directors) at any time. Notwithstanding the preceding sentence, benefits may be distributed to Executives on account of the termination only if: 
  

	(a)	The termination does not occur proximate to a downturn in the financial health of the Company; 

  

	(b)	All nonqualified defined benefit nonaccount-based retirement plans maintained by the Company and all Affiliates that would be aggregated with the Plan under Code section 409A are
terminated when the Plan is terminated; 

  

	(c)	No payments are made within 12 months after the date when the Company takes all steps necessary to terminate and liquidate the Plan, other than payments made pursuant to the
Plan’s otherwise applicable distribution provisions; 

  

	(d)	All benefits are distributed within 24 months after the date when the Company takes all steps necessary to terminate and liquidate the Plan; and 

  

	(e)	Neither the Company nor any Affiliate establishes a new nonqualified, nonaccount-based plan that would be aggregated with the Plan under Code section 409A at any time within
three years after the date when the Company takes all steps necessary to terminate and liquidate the Plan. 

 Such amendment or termination may
modify or eliminate any benefits hereunder other than a benefit that is In Pay Status, or the vested portion of a benefit that is not In Pay Status. 
 8.2 Amendment and Termination Following a Change of Control 
 Notwithstanding the Company’s general right to amend or terminate the Plan
at any time, the Company, including any successor entity to the Company, may not amend or terminate this Plan in any manner following a Change of Control that would adversely affect the rights of an Executive to benefits under this Plan to the
extent such rights are vested as of, or as a result of, such Change in Control. 
  

 26 

 Article 9. Miscellaneous 
 9.1 No Enlargement of Employee Rights 
 This Plan is strictly a voluntary undertaking on the part of the Company and shall not be deemed to
constitute a contract between the Company and any Employee or to be consideration for, or an inducement to, or a condition of, the employment of any Employee. Nothing contained in the Plan shall be deemed to give any Employee the right to be
retained in the service of the Company or any Affiliate or to interfere with the right of any of them to discharge or retire any person at any time. No one shall have any right to benefits, except to the extent provided in this Plan. 
 9.2 Benefit Agreement 
 The Committee shall provide to each Executive
within 60 days of the date the Executive first became an Executive a form of benefit agreement, which shall set forth the Executive’s acceptance of the benefits provided hereunder and his agreement to be bound by the terms of the Plan.

 9.3 Exclusion for Suicide or Self-Inflicted Injury 
 Notwithstanding any other provision of the Plan, no benefits shall be paid to any Executive, or Spouse or Beneficiary in the event of the death of the Executive within two years of the later of the date he first became an Executive or the
date he executed the benefit agreement referred to in Plan section 9.2 as the result of suicide or self-inflicted injury. 
 9.4 Leave of Absence

 An Executive who is on an approved leave of absence with salary, or on an approved leave of absence without salary for a period of not more than six
months, shall be deemed to be an Executive during such leave of absence. An Executive who is on an approved leave of absence without salary for a period in excess of six months shall be deemed to have voluntarily incurred a Separation from
Service as of the end of such six-month period, provided that, based on all relevant facts and circumstances, neither the Executive nor the Company has a reasonable expectation that the Executive will provide future services to the Company or an
Affiliate. 
 9.5 Termination for Good Cause 
 Notwithstanding any provision herein to the contrary, an Executive whose employment with the Company or an Affiliate is terminated for Good Cause shall not be eligible for any benefit hereunder. 
 9.6 Monthly Payments 
 Periodic payments hereunder shall be paid in
equal monthly amounts. 
  

 27 

 9.7 Actuarial Equivalence 
 Actuarial equivalence hereunder shall be determined using the interest and mortality factors adopted from time to time by the Committee. The initial factors to be used shall be the factors used under the Basic Plan for determining actuarial
equivalence. 
 9.8 Withholding 
 Benefit payments
hereunder shall be subject to applicable federal, state or local withholding for taxes. 
 9.9 No Examination or Accounting 
 Neither this Plan nor any action taken thereunder shall be construed as giving any person the right to an accounting or to examine the books or affairs of the Company, or
any Affiliate. 
 9.10 Records Conclusive 
 The records of
the Company shall be conclusive in respect to all matters involved in the administration of the Plan. 
 9.11 Section 409A 
 Notwithstanding any provision of this Plan to the contrary, the Committee shall administer this Plan in a manner designed to comply with Code section 409A and the
Committee shall disregard any Plan provision if the Committee determines that application of such Plan provision would subject the Executive to an additional excise tax under Code section 409A(a)(1)(B). 
 9.12 Service of Legal Process 
 The members of the Committee (or if
there is no such Committee then the Company) are hereby designated as agent(s) of the Plan for the purpose of receiving legal process. 
 9.13 Governing
Law 
 The Plan shall be construed, administered, and governed in all respects under the applicable laws of the State of California, except to the extent
pre-empted by federal law. Upon any change in the law or other determination that any term, condition or other provision of the Plan has been altered in any way, the Committee shall administer this Plan in accordance with such change notwithstanding
the terms of the Plan pending an amendment to this Plan. 
 9.14 Severability 
 If any provision of this Plan is held illegal or invalid for any reason, such illegality or invalidity will not affect the remaining provisions; instead, each provision is fully severable and the Plan will be
construed and enforced as if any illegal or invalid provision had never been included. 
  

 28 

 9.15 Missing Persons 
 The Committee shall establish rules if the Committee is unable to make payment of a benefit due under the terms of the Plan to an Executive because the whereabouts of the Executive cannot be ascertained. 
 9.16 Facility of Payment 
 Every person receiving or claiming benefits
under this Plan is presumed to be mentally competent and of age until the date on which the Committee receives a written notice, in a form and manner acceptable to it, that such person is mentally incompetent or a minor, and that a guardian or other
person legally vested with the care of such person or his estate has been appointed. 
 However, if the Committee should find that any person to whom a
benefit is payable under this Plan is unable to care for his affairs because of any incompetency or is a minor, any payment due (unless a prior claim shall have been made by a duly appointed legal representative) may be paid to the Spouse, a child,
a parent, or a brother or sister, or to any other person or institution that the Committee determines to have incurred expense for such person otherwise entitled to payment. To the extent permitted by law, any such payment so made shall be a
complete discharge of any liability therefor under the Plan. 
 If a guardian of the estate or other person legally vested with the care of the estate of any
person receiving or claiming benefits under the Plan is appointed by a court of competent jurisdiction, payments shall be made to such guardian or other person provided that proper proof of appointment and continuing qualification is furnished in a
form and manner suitable to the Committee. To the extent permitted by law, such guardian or other person may act for the Executive and make any election required of or permitted by the Executive under this Plan, and such action or election shall be
deemed to have been done by the Executive, and benefit payments may be made to such guardian or other person and any such payment shall be a complete discharge of any such liability under the Plan. 
 9.17 General Restrictions Against Alienation 
 The interest of any
Executive under this Plan shall not in any event be subject to sale, assignment, or transfer, and each Executive is hereby prohibited from anticipating, encumbering, assigning, or in any manner alienating his interest hereunder and is without power
to do so; provided, however, that this provision shall not restrict the power or authority of the Committee, in accordance with the applicable provisions of the Plan, to disburse funds to the legally appointed guardian, executor, administrator, or
personal representative of any Executive or pursuant to a valid domestic relations order certified and issued by a court of competent jurisdiction. 
  

 29 

 If any person attempts to take any action contrary to this Plan section 9.17, such action shall be void and the
Company may disregard such action and is not in any manner bound thereby, and they shall suffer no liability for any such disregard thereof. If the Committee is notified that any Executive has been adjudicated bankrupt or has purported to
anticipate, sell, transfer, assign, or encumber any Plan distribution or payment, voluntarily or involuntarily, the Committee shall hold or apply such distribution or payment or any part thereof to, or for the benefit of, such Executive in such
manner as the Committee finds appropriate. 
 9.18 Counterparts 
 This Plan may be executed in any number of counterparts, each of which shall be deemed to be an original. All the counterparts shall constitute but one and the same instrument and may be sufficiently evidenced by any one counterpart.

 9.19 Effect of Amendment on Vested Executives 
 Any
Executive who met the requirements for vesting of his Retirement Income Benefit as of October 31, 2007, shall upon Separation from Service be entitled to receive as his Retirement Income Benefit the greater of 
  

	(a)	The Retirement Income Benefit that such Executive would have been entitled to receive under the Plan as it was in effect on October 31, 2007 (which, for the avoidance of doubt,
was prior to the amendments affected by the amendment and restatement of the Plan effective November 1, 2007) and as if such Executive had a Separation from Service on October 31, 2007 (but not for purposes of the six-month period
described at Plan section 3.5 which shall always be measured from the actual date the Executive experienced a Separation from Service); or 

  

	(b)	The Retirement Income Benefit that such Executive is entitled to receive under the Plan (which, for the avoidance of doubt, is the Plan as amended and restated effective
November 1, 2007). The amendment and restatement effective November 1, 2007, shall not result in the decrease or increase of any Retirement Income Benefit of any Executive who is In Pay Status or any Pre-Retirement Death Benefit being paid
as of October 31, 2007. 

 9.20 Assignment 
 The Company shall have the right to assign its obligations under the Plan, either in whole or in part, to any Affiliate of the Company. 
  

 30 

 In Witness Whereof, the authorized officers of the Company have signed this document and have affixed the
corporate seal on October 31, 2007, but generally effective as of November 1, 2007. 
  

									
		 		 		 	The First American Corporation
			
	Attest:	 		 	
		 		 		 	By	 	 /s/ Parker S. Kennedy

		 		 		 	Its	 	Chairman and CEO
					
	By	 	 /s/ Kenneth D. DeGiorgio
	 		 		 	(Corporate Seal)
	 Its
	 	SVP, General Counsel	 		 	 

  

 31Exclusive License Agreement, dated March 15, 1995 - Hospital for Sick Children

 Exhibit 10.1 
 EXCLUSIVE LICENSE AGREEMENT 
 This EXCLUSIVE LICENSE AGREEMENT is made and is effective this 15th day of March, 1995, by and
between the Hospital for Sick Children, having a principal place of business in Toronto, Canada, hereinafter referred to as “LICENSOR”, and MYRIAD GENETICS, INC., having a principal place of business at 390 Wakara Way, Salt Lake City, Utah
84108, hereinafter referred to as “LICENSEE”. 
 WITNESSETH: 
 WHEREAS, certain genetic research for the isolation, sequencing, and identification of cancer genes is being carried out by [***]; 
 WHEREAS, LICENSEE has certain proprietary information and biological materials concerning the BRCA2 breast cancer gene; 
 WHEREAS, LICENSEE is desirous of collaborating with LICENSOR and obtaining exclusive rights from LICENSOR for the commercial development, use and sale of any inventions that may result from the discovery of the BRCA2
breast cancer gene; 
 NOW THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, it is
agreed by and between the parties, as follows: 
 1. DEFINITIONS 
 1.1 “LICENSED TECHNOLOGY”, as used herein, means technologies, trade secrets, know-how, information, technical data, or materials, including
but not limited to that which relates to research, development, nucleic acid constructions, genes, DNA fragments, gene sequences, bacterial or yeast strains, mammalian cell lines, biological material, chemical compounds, proteins, products,
formulas, substances, experimental plans, inventions, processes, formulations, techniques, methods, designs, data, drawing 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
or other printed, written or electronically stored materials developed by [***] and her co-workers at the Hospital for Sick Children, and which arose from
the research collaboration on the BRCA2 breast cancer gene. To the extent the BRCA2 breast cancer gene is isolated, characterized, developed or sequenced under this research collaboration, LICENSED TECHNOLOGY also includes: 
  

	 	(a)	the human BRCA2 gene(s); 

  

	 	(b)	any fragment(s) of material containing a DNA sequence from the BRCA2 gene(s); 

  

	 	(c)	any BRCA2 protein molecules; 

  

	 	(d)	nucleic acid molecules and monoclonal antibodies that bind to the BRCA2 gene(s) or its DNA sequence; 

  

	 	(e)	any mutations or altered form of the BRCA2 gene(s); 

  

	 	(f)	any animal or human homologues of the BRCA2 gene(s); 

  

	 	(g)	any other “technologies” and/or products developed under this research collaboration required for diagnostic or therapeutic commercial applications of the BRCA2 gene.

 LICENSED TECHNOLOGY further includes all uses of the BRCA2 gene(s) and its products, should they be isolated, characterized, developed or
sequenced under this research collaboration, including such uses as diagnostic and therapeutic applications. 
 1.2 “LICENSOR’S
PATENT RIGHTS”, as used herein, means patent rights to any subject matter claimed in or covered by any pending or issued U.S. and/or foreign patents and applications covering any aspects of LICENSED TECHNOLOGY; any new patents which may
hereinafter be filed covering aspects of LICENSED TECHNOLOGY; any continuing applications thereof; and any patents issuing on said applications or continuing applications including reissues. 
  
 Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 2 

 1.3 “LICENSED PRODUCTS”, as used herein, means any product, apparatus, kit or component part
thereof, or other subject matter whose manufacture, use, or sale is covered by any claim or claims included within LICENSOR’S PATENT RIGHTS. 
 1.4 “LICENSED METHODS”, as used herein, means any method, procedure, process or other subject matter whose manufacture, use, or sale is covered by any claim or claims included within LICENSOR’S PATENT RIGHTS. 
 1.5 “...covered by...”, as used herein, means LICENSED PRODUCTS that when made, used, or sold or LICENSED METHODS that when practiced would
constitute, but for the license granted to LICENSEE pursuant to this Agreement, an infringement of any claim or claims of LICENSOR’S PATENT RIGHTS. 
 1.6 “NET SALES”, as used herein, means the gross income received by LICENSEE—either for (a) LICENSED PRODUCTS sold, or (b) services performed using LICENSED PRODUCT or LICENSED
METHOD—less the sum of the following deductions where applicable: case, trade or quantity discounts; sales, use, tariff, import/ export duties or other excise taxes imposed upon particular sales; transportation charges and allowances or credits
to non-affiliated third parties because of rejections or returns; and uncollectible bad debts. 
 2. GRANT OF LICENSE 
 2.1 Except as otherwise provided herein, LICENSOR hereby grants to LICENSEE an exclusive license under LICENSOR’S PATENT RIGHTS to make, have made,
use, and sell LICENSED PRODUCTS and to practice the LICENSED METHODS throughout the world where LICENSOR may lawfully grant such a license. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 3 

 2.2 The license granted in Paragraph 2.1 above shall be exclusive from the effective date of this
Agreement until the date of expiration of the last to expire of any patents included in LICENSOR’S PATENT RIGHTS. 
 2.3 LICENSOR
retains the right to use LICENSED TECHNOLOGY for its own research and educational purposes. Once the BRCA2 gene has been isolated and sequenced, LICENSEE shall make available to LICENSOR the DNA sequences, primers, cDNAs and other information
concerning the BRCA2 breast cancer gene. 
 2.4 Nothing in this Agreement shall preclude LICENSOR from using publicly available information
to perform future research in the BRCA2 or general cancer areas. 
 3. SUBLICENSES 
 3.1 LICENSOR also grants to LICENSEE the right to issue sublicenses to third parties to make, have made, use and sell LICENSED PRODUCTS and to practice
the LICENSED METHODS. These sublicenses shall include all of the rights and obligations due LICENSOR that are contained in this Agreement. LICENSEE shall pay LICENSOR the royalty rate on NET SALES by such Sublicensees at the same rate that would be
due to LICENSOR from NET SALES by LICENSEE, although LICENSEE is free to charge differential rates to Sublicensees. 
 3.2 LICENSEE shall
provide LICENSOR with a copy of each sublicense issued hereunder; collect and guarantee payment of all royalties due LICENSOR from sublicensees; and summarize and deliver all reports due LICENSOR from sublicensees. 
 4. ROYALTIES 
 4.1 As consideration
for this license, LICENSEE shall pay to LICENSOR an earned royalty of [***] on NET SALES of LICENSED PRODUCTS or LICENSED METHODS during any period where LICENSED PRODUCTS or LICENSED 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 4 

 
METHODS contain non-patentable proprietary LICENSED TECHNOLOGY which is not otherwise available in the public domain or are covered by a pending or issued
patent which has not been abandoned, withdrawn, denied, held invalid or unenforceable in a court of competent jurisdiction. LICENSED PRODUCTS and/or LICENSED METHODS shall be considered sold when invoiced to a third party. All monies due to LICENSOR
shall be payable in United States funds. 
 4.2 Royalties shall accrue in each country for the duration of LICENSOR’S PATENT RIGHTS in
the country, or while non-patentable proprietary LICENSED TECHNOLOGY which is not otherwise available in the public domain exists. 
 4.3
Royalties accruing to LICENSOR shall be paid to LICENSOR within [***] following the end of the calendar quarter in which NET SALES are made. 
 4.4 In the event that any patent or any claim thereof included within the LICENSOR’S PATENT RIGHTS shall be denied, withdrawn or held invalid in a decision by a court of competent jurisdiction and last resort and from which no appeal
has or can be taken, all obligation to pay royalties based on such patent or claim or any claim patentably indistinct therefrom shall cease as of the date of such decision. LICENSEE shall not, however, be relieved from paying any royalties that
accrued before such decision or that are based on another patent or claim not involved in such decision. 
 5. DUE DILIGENCE

 5.1 LICENSEE, upon execution of this Agreement, shall [***] with the development, manufacture, sale and use of LICENSED PRODUCTS and/or
LICENSED METHODS and shall make them readily available to the general public. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 
  

 5 

 5.2 LICENSEE shall be entitled to exercise prudent and justifiable business judgment in meeting its due
diligence obligations hereunder. The parties understand and agree that the due diligence obligations are subject to the LICENSEE’S [***]. 
 6. QUARTERLY REPORTS 
 6.1 After the first occurrence of NET SALES, LICENSEE shall provide LICENSOR with a written report
showing all sales or use made of LICENSED PRODUCTS or LICENSED METHOD during the preceding calendar quarter. If no such sales or use has been made during any reporting period, a statement to this effect shall be required. These reports shall be made
no later than [***] following each calendar quarter. 
 6.2 LICENSEE agrees to report to LICENSOR the date of first occurrence of NET SALES
in each country within [***] of its occurrence. 
 7. BOOKS AND RECORDS 
 7.1 LICENSEE shall keep books and records accurately showing all LICENSED PRODUCTS manufactured, used, or sold under the terms of this Agreement. Such
books and records shall be open to inspection by representatives or agents of LICENSOR at reasonable times and after reasonable advance notice, for the purpose of verifying the accuracy of the quarterly reports and the royalties due or paid.

 7.2 The costs and expenses of the representatives performing such an examination shall be borne by LICENSOR, except that if such
inspection reveals an underpayment of royalties to LICENSOR in excess of [***] for any year, then said inspection shall be at LICENSEE’s expense and such underpayment shall become immediately due and payable to LICENSOR. 
  
 Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 6 

 7.3 These books and records required by Paragraph 7.1 herein shall be preserved for at least [***] from
the date of the royalty payment to which they pertain. 
 8. LIFE OF THE AGREEMENT 
 8.1 This Agreement shall be in full force and effect from the date first herein written and shall remain in effect for the life of the last-to-expire
patent licensed under this Agreement or unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of Article 9 or Article 10 of this Agreement. 
 9. TERMINATION BY LICENSOR 
 9.1 It is expressly agreed that if LICENSEE should
fail to deliver to LICENSOR any statement or report when due, or fail to make any payment, whether fees or royalties, at the time that the same should be due, or if LICENSEE should violate or fail to perform any material covenant, condition, or
undertaking of this Agreement on its part to be performed hereunder, then and in such event LICENSOR may give written notice of such default to LICENSEE. If LICENSEE should fail to repair such default within One Hundred Twenty (120) Days of
such notice or, in the alternative, to request Arbitration, LICENSOR shall have the right to terminate this Agreement and the license herein by written notice to LICENSEE. Upon such notice of termination, this Agreement shall automatically
terminate. Such termination shall not relieve LICENSEE of its obligation to pay any royalty or license fees due or owing at the time of such termination and shall not impair any accrued right of LICENSOR, including but not limited to the recovery of
any costs incurred in the enforcement of such accrued rights. LICENSEE shall pay all attorneys’ fees and court costs incurred by LICENSOR in enforcing any such obligation of LICENSEE or accrued right of LICENSOR after termination. 

 
 Portions of this Exhibit were omitted and have been filed separately with
the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 7 

 10. TERMINATION BY LICENSEE 
 10.1 LICENSEE shall have the right to terminate this Agreement or the license granted herein, in whole or as to any specified patent or claim of such
patent, at any time and from time to time, by giving notice in writing to LICENSOR. Such termination shall be effective Ninety (90) Days from such notice and all LICENSEE’S rights associated therewith shall cease as of that date.

 10.2 Any termination pursuant to the above paragraph shall not relieve LICENSEE of any obligation or liability accrued hereunder prior to
such termination, or rescind or give rise to any right to rescind anything done by LICENSEE or any payments made or other consideration given to LICENSOR hereunder prior to the time such termination becomes effective, and such termination shall not
affect in any manner any rights of LICENSOR arising under this Agreement prior to such termination. 
 11. PATENT PROSECUTION AND
MAINTENANCE 
 11.1 LICENSEE shall [***] prosecute and maintain the United States and foreign patents and patent applications covering
LICENSED TECHNOLOGY as it deems appropriate, using counsel of its choice and after due consultation with LICENSOR. LICENSEE shall provide LICENSOR with copies of all relevant documentation so that LICENSOR may be informed and apprised of the
continuing prosecution and LICENSOR agrees to keep this documentation confidential. All patents will be assigned to [***]. 
 11.2 LICENSEE
agrees to pay all costs and legal fees incurred for the prosecution, maintenance and taxes for patents covering LICENSED TECHNOLOGY and incurred after the effective date of this Agreement. 
  
 Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 8 

 12. PATENT MARKING 
 12.1 LICENSEE agrees to mark all LICENSED PRODUCTS made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. 
 13. WARRANTY BY LICENSOR 
 13.1
LICENSOR warrants that they have the lawful right to grant this license. 
 13.2 LICENSOR makes no express or implied warranties of
merchantability or fitness of LICENSED TECHNOLOGY for a particular purpose. 
 13.3 Nothing in this Agreement shall be construed as:

  

	 	(a)	a warranty or representation by LICENSOR as to the validity or scope of any LICENSOR’S PATENT RIGHTS; or 

  

	 	(b)	a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents of
third parties; or 

  

	 	(c)	an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 14; or 

  

	 	(d)	conferring by implication, estoppel or otherwise any license or rights under any patents of LICENSOR other than LICENSOR’S PATENT RIGHTS as defined herein.

 14. INFRINGEMENT 
 14.1 In the event that LICENSEE shall learn of the infringement of any patent licensed under this Agreement, LICENSEE shall call LICENSOR’S attention thereto. LICENSEE shall use reasonable efforts to terminate such infringement. If
LICENSEE files a lawsuit for patent infringement, LICENSOR shall also be named as a plaintiff. In the event LICENSEE fails to abate the infringing activity within [***], LICENSOR may itself, under its sole discretion, file a lawsuit for patent
infringement, naming LICENSEE as nominal party plaintiff. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended. 
  

 9 

 14.2 Each party agrees to cooperate with the other in litigation proceedings instituted hereunder but at
the expense of the party on account of whom suit is brought. Such litigation shall be controlled by the party bringing the suit. A Party controlling litigation shall reimburse the other for any expenses it incurs in rendering assistance to the Party
controlling the litigation. LICENSOR at its own expense, may be represented by counsel of its choice pursuant to LICENSOR’S determination in any suit brought by LICENSEE. 
 14.3 LICENSEE may withhold royalties payable to LICENSOR during the pendency of the suit and until said suit has been finally concluded. To the extent
that LICENSEE does not recover attorney’s fees and other out-of-pocket costs as a result of such litigation, such withheld royalties may be applied to LICENSEE’S expenses (out-of-pocket and in-house) incurred in connection with such suit
and the balance of such withheld royalties, if any, shall be paid to LICENSOR upon disposition of the suit; provided, however, that if as a result of such suit, all claims of patents included within LICENSOR’S PATENT RIGHTS under which LICENSEE
is selling a LICENSED PRODUCT shall be held invalid, LICENSEE may retain the balance of such withheld royalties which pertain to such LICENSED PRODUCT until such decision shall be finally reversed by an unappealed or unappealable decree of a court
of competent jurisdiction and of higher dignity. 
  
 Portions of
this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

  

 10 

 15. WAIVER 
 15.1 It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default.

 16. ASSIGNABILITY 
 16.1 This Agreement is binding upon and shall inure to the benefit of LICENSOR, its successors and assigns, but shall be personal to LICENSEE and assignable by LICENSEE only with the written consent of LICENSOR, which consent shall not be
unreasonably withheld; provided, however, that LICENSEE, without consent, may assign or sell the same in connection with the transfer or sale of all or substantially all of its business relating to LICENSED PRODUCTS or LICENSED METHODS or in the
event of merger or consolidation with another company. 
 17. INDEMNITY 
 17.1 LICENSEE agrees to indemnify, hold harmless and defend LICENSOR, its officers, employees, and agents, against any and all claims, suits, losses,
damage, costs, fees and expenses resulting from or arising out of exercise of this license. 
 18. LATE PAYMENTS 
 18.1 In the event royalty payments or fees are not received by LICENSOR when due, LICENSEE shall pay to LICENSOR interest charges at the rate of [***]
per annum on the total royalties or fees due for the reporting period. 
 19. NOTICES 
 19.1 Any payment, notice or other communication required or permitted to be given to either party hereto shall be deemed to have been properly given and
to be effective on the date of delivery if delivered in person or on the fourth day after mailing if 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 11 

 
mailed by first-class certified or registered mail, postage paid, to the respective address given below, or to such other address as it shall designate by
written notice given to the other party as follows: 
 In the case of LICENSEE: 
 MYRIAD GENETICS, INC. 
 390 Wakara Way

 Salt Lake City, Utah 84108 
 Attention: President 
 In the case of LICENSOR: 
 HOSPITAL FOR SICK CHILDREN 
 555 University Avenue 
 Toronto, Ontario 
 Canada M5G1X8 

Attn: Technology Licensing 
 20. FOREIGN
LAWS REGISTRATION 
 20.1 LICENSEE agrees to register this Agreement when required by local/national law, to pay all costs and legal fees
connected therewith, and to otherwise insure that the local/ national laws affecting this Agreement are fully satisfied. 
 20.2 LICENSEE
agrees to abide by all U.S. technology export regulations. 
 21. GOVERNING LAWS 
 21.1 This Agreement shall be interpreted and construed in accordance with the laws of the State of Utah. 
 22. SURVIVAL OF OBLIGATIONS 
 22.1 In
the event of expiration of the Agreement pursuant to Section 8.1 or termination of the Agreement pursuant to Sections 9.1 or 10.1, the obligations under Sections 7, 13, 17, 20, and 23.6 and obligations to pay royalties and other sums accruing
hereunder up to the day of such termination shall remain in force beyond the termination date. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 
  

 12 

 23. MISCELLANEOUS 
 23.1 The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 
 23.2 This Agreement will not be binding upon the parties until it has been signed herein below by or on behalf of each party, in which event, it shall be
effective as of the date first above written. 
 23.3 No amendment or modification hereof shall be valid or binding upon the parties unless
made in writing and signed as aforesaid. 
 23.4 This Agreement embodies the entire understanding of the parties and shall supersede all
previous communications, representations or understandings either oral or written between the parties relating to the subject matter hereof. 
 23.5 In case any one or more of the provisions contained in this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other
provisions hereof, but this Agreement shall be construed as if such invalid or illegal or unenforceable provisions had never been contained herein. 
 23.6 LICENSEE agrees to refrain from using and to require sublicensees to refrain from using the name of LICENSOR and The Hospital for Sick Children in publicity or advertising without the prior written approval of that entity. 

23.7 The relationship between the Parties is that of independent contractor and contractee. LICENSEE shall not be deemed to be an agent of LICENSOR in
connection with the exercise of any rights hereunder, and shall not have any right or authority to assume or create any obligation or responsibility on behalf of LICENSOR. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 13 

 23.8 No Party hereto shall be deemed to be in default of any provision of this Agreement, or for any
failure in performance, resulting from acts or events beyond the reasonable control of such Party, such as but not limited to, Acts of God, acts of civil or military authority, civil disturbance, war, strikes, fires, power failures, natural
catastrophes or other “force majeure” events. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended. 
  

 14 

 IN WITNESS WHEREOF, both LICENSOR and LICENSEE have executed this Agreement, in duplicate originals, by
their respective officers hereunto duly authorized, on the day and year hereinafter written. 
  

									
	MYRIAD GENETICS, INC.	 		 	HOSPITAL FOR SICK CHILDREN
					
	By	 	 /s/ Peter D. Meldrum
	 		 	By	 	 /s/ George H. [    ]

		 	(Signature)	 		 		 	(Signature)
	Name	 	Peter D. Meldrum	 		 	Name	 	George H. [    ]
	Title	 	President and CEO	 		 	Title	 	Associate Director of Administration
					
	Date	 	3/15/95	 		 	Date	 	3/30/95

  
 Portions of this
Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]